Apatinib as first-line treatment in patients with advanced hepatocellular carcinoma: a phase II clinical trial

Background The prognosis for advanced hepatocellular carcinoma (HCC) remains clinically unsatisfying. Apatinib has proven to be a very effective treatment for advanced HCC in our previous retrospective study. Our aim in this study was to evaluate the efficacy, safety, and toxicity of apatinib in patients with advanced HCC. Methods This single-arm, open-label phase II clinical trial enrolled patients with advanced HCC. These patients received apatinib, 500 mg once daily, until disease progression, unacceptable toxicity, consent withdrawal, or death. One treatment cycle consisted of 4 weeks of apatinib treatment. The response evaluation criteria in solid tumors (RECIST) was used to assess tumor response every 1–2 cycles. The primary endpoint was the objective response rate (ORR), while the secondary endpoints were the overall survival (OS), progression-free survival (PFS), disease control rate (DCR), and toxicity. Results Between December 2016 and June 2018, 23 patients were enrolled in the study, 22 of whom were available for response evaluation. The cutoff date was August 10, 2018. The overall ORR and DCR were 30.4% and 65.2%, respectively. The median OS and PFS were 13.8 (95% CI: 5.3–22.3) and 8.7 (95% CI: 5.9–11.1) months, respectively. The most common treatment-related adverse events were proteinuria (39.1%), hypertension (34.8%), and hand-foot-skin reaction (34.8%). Conclusions Apatinib showed robust clinical activity in patients with advanced HCC. Moreover, apatinib was safe to use, well tolerated, and had acceptable toxicity. (NCT03046979).

[1]  W. Fan,et al.  Apatinib Combined With Transarterial Chemoembolization in Patients With Hepatocellular Carcinoma and Portal Vein Tumor Thrombus: A Multicenter Retrospective Study. , 2019, Clinical therapeutics.

[2]  E. Schmidt,et al.  Lenvatinib plus pembrolizumab in patients with advanced endometrial cancer: an interim analysis of a multicentre, open-label, single-arm, phase 2 trial. , 2019, The Lancet. Oncology.

[3]  Changcun Guo,et al.  Clinical efficacy of TACE combined with Apatinib in the treatment of advanced hepatocellular carcinoma. , 2019, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

[4]  F. Hirsch,et al.  Low-Dose Apatinib Optimizes Tumor Microenvironment and Potentiates Antitumor Effect of PD-1/PD-L1 Blockade in Lung Cancer , 2019, Cancer Immunology Research.

[5]  Wenchang Yu,et al.  Comparison of the efficacy and safety of Transarterial chemoembolization with and without Apatinib for the treatment of BCLC stage C hepatocellular carcinoma , 2018, BMC Cancer.

[6]  M. Kudo.  Systemic Therapy for Hepatocellular Carcinoma: Latest Advances , 2018, Cancers.

[7]  X. Yi,et al.  Anti-PD-1 Antibody SHR-1210 Combined with Apatinib for Advanced Hepatocellular Carcinoma, Gastric, or Esophagogastric Junction Cancer: An Open-label, Dose Escalation and Expansion Study , 2018, Clinical Cancer Research.

[8]  Long Jin,et al.  The safety and efficacy of TACE combined with apatinib on patients with advanced hepatocellular carcinoma: a retrospective study , 2018, Cancer biology & therapy.

[9]  M. Zheng,et al.  Apatinib combined with oral etoposide in patients with platinum-resistant or platinum-refractory ovarian cancer (AEROC): a phase 2, single-arm, prospective study. , 2018, The Lancet. Oncology.

[10]  P. Schirmacher,et al.  EASL Clinical Practice Guidelines: Management of hepatocellular carcinoma. , 2018, Journal of hepatology.

[11]  M. Kudo,et al.  Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial , 2018, The Lancet.

[12]  Jing Zhao,et al.  Successful treatment using apatinib with or without docetaxel in heavily pretreated advanced non-squamous non-small cell lung cancer: A case report and literature review , 2018, Cancer biology & therapy.

[13]  Lin Sun,et al.  Apatinib is effective for treatment of advanced hepatocellular carcinoma , 2017, Oncotarget.

[14]  Ying Cheng,et al.  Randomized, Double-Blind, Placebo-Controlled Phase III Trial of Apatinib in Patients With Chemotherapy-Refractory Advanced or Metastatic Adenocarcinoma of the Stomach or Gastroesophageal Junction. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[15]  A. Loaiza-Bonilla,et al.  Immune checkpoint inhibitors for hepatocellular carcinoma. , 2016, Hepatic oncology.

[16]  J. Ragaz,et al.  Multicenter phase II study of apatinib, a novel VEGFR inhibitor in heavily pretreated patients with metastatic triple‐negative breast cancer , 2014, International journal of cancer.

[17]  A. Tsimberidou,et al.  Anti-vascular endothelial growth factor therapy in the era of personalized medicine , 2013, Cancer Chemotherapy and Pharmacology.

[18]  S. Sleijfer,et al.  Cardiovascular and renal toxicity during angiogenesis inhibition: clinical and mechanistic aspects , 2009, Journal of hypertension.

[19]  S. Paggi,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[20]  Anil K Sood,et al.  Angiogenesis as a strategic target for ovarian cancer therapy , 2008, Nature Clinical Practice Oncology.

[21]  M. Cooney,et al.  Hypertension, proteinuria, and antagonism of vascular endothelial growth factor signaling: clinical toxicity, therapeutic target, or novel biomarker? , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[22]  J. Verweij,et al.  The clinical toxicity profile of vascular endothelial growth factor (VEGF) and vascular endothelial growth factor receptor (VEGFR) targeting angiogenesis inhibitors; a review. , 2006, European journal of cancer.

[23]  Jeffrey W. Clark,et al.  A phase II study of epirubicin and thalidomide in unresectable or metastatic hepatocellular carcinoma. , 2005, The oncologist.

[24]  G. Déléris,et al.  Vascular endothelial cell growth factor (VEGF), an emerging target for cancer chemotherapy. , 2003, Current medicinal chemistry. Anti-cancer agents.

[25]  Y. Gho,et al.  Endostatin Blocks Vascular Endothelial Growth Factor-mediated Signaling via Direct Interaction with KDR/Flk-1* , 2002, The Journal of Biological Chemistry.

[26]  L. Claesson‐Welsh,et al.  FGF and VEGF function in angiogenesis: signalling pathways, biological responses and therapeutic inhibition. , 2001, Trends in pharmacological sciences.

[27]  S. Jiang,et al.  Role of vascular endothelial growth factor in the stimulation of cellular invasion and signaling of breast cancer cells. , 2001, Cell growth & differentiation : the molecular biology journal of the American Association for Cancer Research.

[28]  Guías de Práctica Clínica.  European Association for the Study of the Liver , 1971 .

[29]  G. McCaughan,et al.  Epidemiology and Etiologic Associations of Non-alcoholic Fatty Liver Disease and Associated HCC. , 2018, Advances in experimental medicine and biology.

[30]  J. Soria,et al.  VEGF signalling inhibition-induced proteinuria: Mechanisms, significance and management. , 2010, European journal of cancer.

[31]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.

[32]  G. Deray,et al.  Hypertension and proteinuria: a class-effect of antiangiogenic therapies. , 2009, Anti-cancer drugs.

[33]  W. Cai,et al.  Vascular endothelial growth factor and vascular endothelial growth factor receptor inhibitors as anti-angiogenic agents in cancer therapy. , 2007, Recent patents on anti-cancer drug discovery.

[34]  Liver Cancer Study Group of Japan.  The general rules for the clinical and pathological study of primary liver cancer , 2006, The Japanese journal of surgery.

[35]  D. Woodfield.  Hepatocellular carcinoma. , 1986, The New Zealand medical journal.